A Novel Self-Expanding Interwoven Nitinol Stent for Complex Femoropopliteal Lesions: 24-Month Results of the SUPERA SFA Registry

Abstract

Over a 2-year surveillance period, excellent durability without stent fractures was documented after implantation of the SUPERA stent in complex femoropopliteal lesions. In addition, significant improvements were observed in symptom classification and hemodynamics.

Wire-Interwoven Nitinol Stent Outcome in the Superficial Femoral and Proximal Popliteal Arteries

“…Of 243 stents in 228 patients evaluated with rigorous radiographic follow-up, none (0/243) had evidence of fracture. These results are consistent with those reported in 2 published registry analyses of the Supera stent in the SFA 27 and popliteal artery, 28 which demonstrated 12-month patency rates of 85% and 88%, respectively, and no stent fractures identified.…”

Evolution of surgical techniques for a progressive risk reduction

“…In the course of recent years, drug-eluting balloons (DEBs) have been created, as well as new types of stent both metallic and medicated (drug-eluting stent, DES), covered stent grafts, and new systems of atherectomy to reduce the incidence of restenosis and improve the long term outcomes. The second-generation nitinol stents have a greater flexibility, particularly in the axial sense, and more resistance to fracture, characteristics which make these stents indicated also for the treatment of more complex lesions; the SUPERA SFA registry enrolled 107 patients with complex femoropopliteal lesions treated with insertion of a Supera stent, showing a patency rate of 76% at 24 months [4]. Today, PTA with a DEB, hence without stent placement, is becoming more and more common.…”

Drug-Eluting Stents Are the Default Strategy for Superficial Femoral Artery Intervention Now

“…[47][48][49] This device is the most expensive bare metal stent, requires meticulous vessel preparation, and is technically challenging to deploy. These data lend strong support to stent placement being superior to PTA as a means to reduce restenosis and TlR, and to improve meaningful clinical outcomes.…”